Bank Of New York Mellon Corp Aveo Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.48 - $14.97 $455,655 - $804,383	53,733 New	53,733 $803,000
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $106,758 - $140,836	16,151 New	16,151 $133,000
Q4 2021 Feb 11, 2022	SELL	$4.69 - $7.4 $58,925 - $92,973	-12,564 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.12 - $6.89 $41,062 - $55,257	-8,020 Reduced 38.96%	12,564 $78,000
Q2 2021 Aug 11, 2021	SELL	$6.21 - $7.45 $238,867 - $286,564	-38,465 Reduced 65.14%	20,584 $135,000
Q1 2021 May 13, 2021	BUY	$5.97 - $15.28 $2,602 - $6,662	436 Added 0.74%	59,049 $432,000
Q4 2020 Feb 09, 2021	BUY	$5.08 - $6.68 $32,512 - $42,752	6,400 Added 12.26%	58,613 $338,000
Q3 2020 Nov 12, 2020	BUY	$4.16 - $6.26 $40,684 - $61,222	9,780 Added 23.05%	52,213 $310,000
Q2 2020 Aug 12, 2020	BUY	$3.47 - $9.99 $147,242 - $423,905	42,433 New	42,433 $218,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.